ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

50-Gene Set Identifies Known Types Of Breast Cancer

February 27, 2009

U.S. Tobacco Program Loses $505 il. In Loan Principle, Report Finds

January 5, 1990

US Oncology Inc. Asked For Drug Purchase Information.

July 4, 2003

Advisers Discuss What To Do About Physician-Scientists

May 1, 1992

TGen’s Trent To Lead Van Andel Institute

February 13, 2009

Partial Responses To Zactima In Thyroid Cancer Trial

January 27, 2006